With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Building off an earlier pilot trial, the phase 3 CheckMate-816 has announced it confirms the addition of nivolumab to neoadjuvant chemo for resectable non-small cell lung cancer improves pathologic complete response rates. | Bristol Myers Squibb 2020
Comments
Post a Comment